Lack of a dose response across the three levels of drug tested in part A of the phase II/III turned out to be no big deal for Cara Therapeutics Inc., which scored positive top-line results from its 174-patient experiment showing that intravenous CR845 hit statistical significance on primary and secondary endpoints for efficacy (reduced itching and improved quality of life, respectively) in patients with uremic pruritus (UP).